Skip to main content
Premium Trial:

Request an Annual Quote

Ambry Genetics Named Service Provider for Roche NimbleGen Target-Enrichment Tech


Roche NimbleGen said today that genomic services provider Ambry Genetics has become a certified service provider for the NimbleGen SeqCap EZ Exome workflow.

Ambry, based in Aliso Viejo, Calif., will provide target enrichment services using SeqCap EZ Human Exome combined with next-generation sequencing services.

The SeqCap EZ Exome technology uses a single tube of stable DNA oligos to capture all exons in solution in a simple, scalable workflow, and contains 2.1 million empirically optimized DNA probes, according to Roche NimbleGen.

Under the partnership, Ambry will process customer genomic DNA samples for enrichment using SeqCap to capture all human coding exons, and sequence the enriched samples using short-read, paired-end sequencing, Roche NimbleGen said.

Ambry becomes Roche NimbleGen's first service provider in the US, the companies said.

Roche NimbleGen CEO Frank Pitzer said in a statement that Ambry's genomics and next-gen sequencing services were "an ideal fit" with the SeqCap EZ Exome technology, and that the partnership will provide more researchers with access to the technology.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.